Revenue

A new partnership aims to bring cutting-edge cancer trials to community clinics, accelerating drug development and expanding patient access to care.

858 Therapeutics' novel PARG inhibitor offers new hope for patients with a deadly, drug-resistant form of ovarian cancer, accelerating its path to approval.

Accenture's new investment in Profitmind's agentic AI platform signals a major shift for retail, promising to automate complex decisions and bridge the gap between data and action.

The new x-hoppers mobile app bridges the gap between the frontline and back office, creating a unified, AI-powered communication network for all staff.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

A new study on a compact, wireless robotic device could democratize access to precision knee surgery, thanks to pioneering work from a rural Missouri surgeon.

Collegium Pharmaceutical projects robust 2026 revenue fueled by its ADHD drug Jornay PM, savvy debt refinancing, and a proactive generic strategy.

Echo Water's new Echo One promises ultra-pure, hydrogen-rich water on demand. But is the cutting-edge science and technology worth the premium price tag?

Quantum PKI appoints Dr. Judy Gounden as CEO, signaling a strategic push for global growth, crypto-agility, and diverse leadership in digital trust.

With record growth and a fortified cash position, ElevateBio combines AI-driven discovery and industrial-scale manufacturing to power the gene therapy boom.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

Keystone doubles down on AI advisory with Audax Private Equity's backing, spinning off its supply chain software unit into a new powerhouse, Keystone AI.

With nearly $30M in new funding, fintech firm Obita is building a blockchain-based network to tackle the high costs and delays of global B2B transactions.

The pet franchise doubled its stores in 3 years, achieving $150M in sales. Its rapid rise reflects a booming market and a new competitive landscape.

A new alliance between fintech innovators K1x and Juno promises to automate the most dreaded part of tax season, freeing CPAs from manual data entry.

The opioid treatment specialist projects over $1.1B in revenue, driven by its flagship drug SUBLOCADE and a major strategic overhaul in the U.S.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

The medtech firm's preliminary results show a Q4 revenue uptick but miss yearly estimates, signaling a stabilizing but cautious path forward for 2026.

Otis secures a major TfL contract to upgrade 172 escalators, blending a century of history with future-ready tech for a smarter, more reliable commute.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.